Stockscreener 앱 받기
11.45
2.97%
-0.35
전일 마감가:
$11.80
열려 있는:
$11.8
하루 거래량:
1.16M
Relative Volume:
0.61
시가총액:
$1.33B
수익:
-
순이익/손실:
$-294.51M
주가수익비율:
-3.2163
EPS:
-3.56
순현금흐름:
$-244.42M
1주 성능:
-5.22%
1개월 성능:
-13.06%
6개월 성능:
-66.15%
1년 성능:
-59.67%
1일 변동 폭
$11.24
$11.99
1주일 범위
$10.72
$12.43
52주 변동 폭
$10.72
$47.45
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
DYN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
11.45 | 1.33B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
다인 테라 Stock (DYN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 재확인 | Chardan Capital Markets | Buy |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | H.C. Wainwright | Buy |
| 2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 개시 | Oppenheimer | Outperform |
| 2023-01-26 | 개시 | Guggenheim | Buy |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Outperform |
| 2020-10-12 | 개시 | JP Morgan | Overweight |
| 2020-10-12 | 개시 | Jefferies | Buy |
| 2020-10-12 | 개시 | Piper Sandler | Overweight |
| 2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
BMO maintains Dyne Therapeutics stock with $50 target By Investing.com - Investing.com Canada
Dyne names Editas’ Erick Lucera CFO - BioCentury
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path - Benzinga India
Sector Update: Health Care Stocks Steady Premarket Friday -March 21, 2025 at 09:24 am EDT - Marketscreener.com
JPMorgan cuts Dyne Therapeutics stock target to $17 from $18 By Investing.com - Investing.com Canada
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer - The National Law Review
Dyne Therapeutics Appoints Erick Lucera as Chief Financial Officer - citybiz
Dyne Therapeutics names new CFO ahead of clinical milestones By Investing.com - Investing.com South Africa
Dyne Therapeutics Names Erick Lucera as CFO -March 20, 2025 at 05:36 pm EDT - Marketscreener.com
Dyne Therapeutics Appoints Erick Lucera as CFO - TipRanks
Dyne Therapeutics Announces Appointment of Erick J. Lucera As Chief Financial Officer - Marketscreener.com
Dyne Therapeutics names new CFO ahead of clinical milestones - Investing.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq - GlobeNewswire
New Dyne Therapeutics CFO Secures Major Equity Package Worth 280,600 Shares - StockTitan
Dyne Therapeutics Strengthens Commercial Launch Plans With Strategic CFO Appointment - StockTitan
(DYN) Technical Data - Stock Traders Daily
Dyne reports new long-term data from Phase 1/2 DELIVER trial of DYNE-251 - MSN
Stifel maintains Buy on Dyne Therapeutics with $66 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains $46 target on Dyne Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $46 target on Dyne Therapeutics stock - Investing.com
Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results - Marketscreener.com
Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect - BioSpace
Dyne Therapeutics Announces New Long-Term Clinical Data - GlobeNewswire
Dyne : Phase 1/2 Trial Of DYNE-251 In DMD Shows Sustained Functional Improvements Through 18 Months - Nasdaq
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months - The Manila Times
Dyne Therapeutics Reports Promising Long-Term Data for DYNE-251 in Duchenne Muscular Dystrophy with Plans for Accelerated Approval Submission - Nasdaq
Game-Changing DMD Clinical Trial: Dyne's DYNE-251 Achieves 8.72% Dystrophin Expression - StockTitan
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages - Defense World
Dyne wins new Outperform at BMO on prospects for lead drug - MSN
BMO Capital Markets Begins Coverage on Dyne Therapeutics (NASDAQ:DYN) - Defense World
Dyne therapeutics chief commercial officer sells $1,733 in stock By Investing.com - Investing.com Australia
Dyne therapeutics chief commercial officer sells $1,733 in stock - Investing.com
Dyne Therapeutics chief scientific officer sells shares worth $24,501 By Investing.com - Investing.com South Africa
Dyne Therapeutics chief scientific officer sells shares worth $24,501 - Investing.com India
GDX Is Looking To Retest 2020 Highs; Gold To 3K Soon? - The Globe and Mail
Dyne: Accelerated Approval DYNE-101 Might Be Possible With Surrogate Biomarker (DYN) - Seeking Alpha
BMO Capital Initiates Coverage of Dyne Therapeutics (DYN) with Outperform Recommendation - MSN
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks - Yahoo Finance
BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating - Yahoo Finance
BMO Capital Initiates Dyne Therapeutics Inc at Outperform With $50 Price Target -March 12, 2025 at 07:22 am EDT - Marketscreener.com
Dyne Therapeutics: Innovative Approaches and Promising Clinical Programs Drive Buy Rating - TipRanks
Dyne Therapeutics initiated with an Outperform at BMO Capital - TipRanks
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum - GlobeNewswire
Neuromuscular Disease Breakthroughs: Dyne Therapeutics Reveals Latest Progress at CNS Forum - StockTitan
Dyne Therapeutics (NASDAQ:DYN) Research Coverage Started at Scotiabank - Defense World
Critical Analysis: Dyne Therapeutics (NASDAQ:DYN) and Lantern Pharma (NASDAQ:LTRN) - Defense World
Trend Tracker for (DYN) - Stock Traders Daily
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Scotiabank - MarketBeat
Scotiabank Initiates Coverage of Dyne Therapeutics (DYN) with Sector Outperform Recommendation - Nasdaq
Dyne Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Thinking Of Investing In Dyne Therapeutics Inc (NASDAQ: DYN) Stock? Read This First - Stocks Register
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.34%
자본화:
|
볼륨(24시간):